Please login to the form below
New accounts: December - PR & Med Ed
The following tables list new pharmaceutical account wins notified to us by the winning agencies for the period September to November 2006 inclusive
|
|
|
|
|
|
Cephalon |
Targretin |
Oncology |
LeapFrog Medical |
|
Gr˙nenthal |
Analgesic product portfolio |
Pain |
Munro & Forster |
|
Gr˙nenthal |
Belara Publication Plan |
Gynaecology |
Zaicomm MMC |
|
MSD |
Univadis website |
N/A |
LeapFrog Medical |
|
Novo Nordisk |
Healthspan range |
Vitamins and minerals |
Spink Consumer Relations |
|
Oraldent |
Gengigel |
Oral treatment |
Ware Anthony Rust |
|
Pfizer UK |
Macugen |
Ophthalmology |
Zaicom MMC |
|
Pfizer UK |
Vfend |
Anti-infectives |
Zaicom MMC |
|
Quintiles (international) |
Phase I trials |
Corporate communications |
Huntsworth Health |
|
Reckitt Benckiser (global) |
Nurofen |
Pain |
Virgo Health PR |
|
Roche Products UK |
Bondronat |
Oncology |
Just:: |
|
Solvay |
Creon |
Cystic fibrosis |
LeapFrog Medical |
|
Takeda Europe |
Actos |
Type II diabetes |
The Remedy, Fleishman-Hillard |
|
Takeda Europe |
Blopress |
Hypertension |
The Remedy, Fleishman-Hillard |
|
Takeda Europe |
Prostap SR |
Prostate cancer |
The Remedy, Fleishman-Hillard |
|
Takeda Europe |
Rozerem |
Insomnia |
The Remedy, Fleishman-Hillard |
|
Takeda Europe |
International medical meetings |
N/A |
The Remedy, Fleishman-Hillard |
|
TCN |
Corporate PR |
Independent healthcare |
Zaicom MMC |
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
- New data backs remdesivir for COVID-19, but rings hydroxychloroquine alarm bell
- How will the events and exhibitions industry change post-Coronavirus?
- UK government and GSK/Sanofi sign COVID-19 vaccine supply deal
- COVID-19 round-up: WHO pulls hydroxychloroquine study, UK restricts dexamethasone exports, and more
- Moderna’s COVID-19 vaccine enters pivotal phase 3 trial
- The blurred lines between sepsis and COVID-19
- Article: What's next? How behavioural science can support pharma's future
- US secures 100 million doses of Sanofi/GSK’s COVID-19 vaccine
- UK will provide millions of 90-minute COVID-19 tests over the coming months
- NeuroRx, Relief Therapeutics’ COVID-19 drug demonstrates early potential
- Video: UX/ Experience design research
- White paper: The impact of COVID-19 on chronic disease management
PMHub
Four Health
Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...
Latest intelligence
- Article: What's next? How behavioural science can support pharma's future
- ...
- Video: UX/ Experience design research
- ...
- White paper: The impact of COVID-19 on chronic disease management
- ...
Quick links
Infographics
